No Detail Found!

Antibody response to the covid-19 vaccine among pregnant women: a prospective study

Author(s)
ZAHRA SS Department of Gynecology, Bahawalpur Medical & Dental College & Hospital Bahawalpur, Pakistan
DARS S Department of Gynecology, Liaquat University of Medical & Health Sciences (LUMHS) Jamshoro, Pakistan.
KUMARI S Department of Gynecology Khadmat Khaliq Foundation Medical Complex Hyderabad, Pakistan.
SAHAR B Department of Gynecology, Buch International Hospital, Multan, Pakistan
WAHID A Department of Gynecology, DG Khan Medical College & Hospital, Pakistan
EJAZ ST Department of Gynecology, DG Khan Medical College & Hospital, Pakistan
Abstract
The study's objective was to investigate the antibody responses and fetal and maternal adverse effects of the Sinopharm vaccine. A prospective study was conducted in The Gynaecology Department of LUMHS Hospital Jamshoro, Hyderabad, Multan and DG Khan from January 2021 to January 2022. A total of 90 women were included in the study who were administered Sinopharm. 3/90 (3.3%) women received shots in 1st trimester, 56/90 (62%) in 2nd trimester and 31/90 (34%) in 3rd trimester. ELISA measured SARS-CoV-2 receptor binding domain (RBD) specific total antibodies and ACE2 blocking antibodies. The adverse effects on the mother and fetus were evaluated after the delivery. The vaccine administration showed no harmful effects or pregnancy-related complications like congenital anomalies, miscarriage, preterm delivery, thrombotic events, fetal death, or hypertensive disorders. SARS-CoV-2 specific total antibodies were found in 57/90 (63%) women at the time of recruitment (when receiving 1st dose); thus, they were considered to be previously infected. The whole sample was seroconverted after 2nd dose. Significantly high levels of RBD binding antibodies and ACE2 blocking antibodies were observed in previously infected women after administration of the second dose compared to uninfected individuals. The Sinopharm vaccine showed positive results in pregnant women and induced high seroconversion rates and ACE2-blocking antibodies in 2nd and 3rd trimester.
Publication Details
Page(s) 1-4
Published Journal: Biological and Clinical Sciences Research Journal, Volume: 4, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
Pregnant women, SARS-CoV-2, ACE2 Blocking Antibodies, Receptor Binding Antibodies
0

Citations

0

Downloads

55

Views